Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when combined with carboplatin and pemetrexed in the treatment of KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) in adults. The confirmed objective response rate (ORR) and disease control rate (DCR) in treatment-naive patients were 65% and 100%, respectively, while in the second-line setting, these rates were 54% and 85%, respectively. Among a cohort with PD-L1 expression levels below 1%, the ORR slightly decreased to 62% in the first-line and to 50% in the second-line.
Encouraging Trial Performance and Late-Stage Study Advancement
The performance in this Phase Ib/II trial has been encouraging enough for Amgen to progress the candidate therapy to a late-stage study. The company plans to conduct a late-stage study focusing on first-line KRAS G12C-mutant and PD-L1 negative advanced NSCLC patients. This advancement highlights the potential of Lumakras in providing effective treatment options for patients with specific KRAS mutations in NSCLC.-Fineline Info & Tech
